Jaguar Health, Inc. (JAGX) Key Metrics
JAGX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $6.9M
- Enterprise value
- $19.1M
- P/E (TTM)
- —
- Forward P/E
- 200.0
- PEG ratio
- —
- Price / sales
- 0.2
- Price / book
- 0.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.10
JAGX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsJAGX returns How much profit the business earns on the capital it uses.
JAGX financial health Debt, liquidity and how easily interest is covered.
JAGX efficiency & capital use Working capital cycle and where the cash goes.
JAGX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
JAGX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
JAGX cash returned to shareholders
JAGX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $488.88 | $13,256.25 | $119,227.50 | $998,156.25 | $998,156.25 | $992,250.00 | $992,250.00 | $1,240,312.50 | $186,046,874,981,395,328.00 | $186,046,874,981,395,328.00 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | −628.6% | — | — | −365.1% | −242.6% | −480.1% | −283.9% | −296.7% | — |
| Return on invested capital (ROIC) | −116.5% | −68.2% | −84.3% | −103.3% | −130.6% | −105.1% | −136.0% | −93.6% | −160.9% | −684.4% |
| Return on assets (ROA) | −116.5% | −73.9% | −84.1% | −94.2% | −109.4% | −85.3% | −99.5% | −75.9% | −93.1% | −184.5% |
| Return on tangible assets | −239.6% | −110.1% | −134.8% | −189.7% | −171.8% | −182.7% | −371.1% | −344.5% | −437.5% | −413.5% |
| Free cash flow margin | 50.2% | −253.4% | −340.6% | −290.9% | −806.8% | −162.9% | −354.2% | −514.9% | −225.3% | — |
| Financial health | ||||||||||
| Total debt | $43.6M | $36.5M | $37.1M | $34.8M | $29.4M | $16.2M | $7.6M | $16.1M | $16.4M | $3.9M |
| Cash & short-term investments | $968,000 | $8.0M | $6.5M | $5.5M | $17.1M | $8.1M | $3.5M | $2.6M | $520,698 | $950,979 |
| Net debt | $42.6M | $28.5M | $30.6M | $29.4M | $12.3M | $8.1M | $4.1M | $13.5M | $15.9M | $2.9M |
| Debt / equity | — | 5.01 | 7.48 | — | 2.53 | 0.94 | 0.71 | 2.99 | 0.95 | — |
| Debt / assets | 1.14 | 0.68 | 0.73 | 0.73 | 0.55 | 0.38 | 0.21 | 0.39 | 0.38 | 1.09 |
| Current ratio | 0.50 | 1.63 | 2.00 | 0.74 | 1.84 | 1.35 | 0.62 | 0.31 | 0.25 | 0.61 |
| Quick ratio | 0.29 | 1.11 | 1.34 | 0.50 | 1.52 | 1.14 | 0.48 | 0.18 | 0.11 | 0.51 |
| Interest coverage | -673.3 | -133.5 | -5.4 | -2.7 | -4.8 | -9.5 | -5.1 | -11.7 | -28.3 | -13.8 |
| Working capital | −$20.3M | $12.5M | $14.0M | −$8.0M | $13.0M | $4.6M | −$5.9M | −$18.5M | −$11.6M | −$1.6M |
| Invested capital | $25.4M | $35.8M | $35.6M | $28.7M | $23.9M | $25.3M | $14.7M | $18.9M | $33.1M | $482,037 |
| Tangible asset value | −$34.7M | −$12.0M | −$15.2M | −$23.8M | −$10.8M | −$7.1M | −$15.4M | −$26.3M | −$21.3M | −$2.5M |
| Net current asset value | −$36.7M | −$14.7M | −$17.9M | −$26.5M | −$13.0M | −$7.8M | −$16.2M | −$27.5M | −$22.6M | −$3.5M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | $33,000 | — | $12.2M | $0 | $0 |
| Share buybacks (net) | $31.1M | — | — | — | — | $0 | $0 | $30 | $0 | $0 |
| Dividends + buybacks / free cash flow | 538.1% | — | — | — | — | — | — | — | — | — |
| Capex / revenue | 0.2% | 2.0% | 0.0% | 14.0% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 73.6% |
| Capex / operating cash flow | 0.4% | — | — | — | — | — | — | — | — | — |
| Capex / depreciation | 0.01 | 0.10 | 0.00 | 0.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 2.19 |
| Stock-based compensation / revenue | −7.0% | 14.0% | 21.6% | 27.8% | 91.7% | 30.1% | 51.8% | 45.8% | 18.7% | 507.3% |
| R&D / revenue | 216.9% | 141.5% | 190.5% | 147.6% | 347.8% | 68.3% | 100.8% | 116.7% | 97.9% | 5,092.4% |
| SG&A / revenue | 226.1% | 205.5% | 236.1% | 223.4% | 599.7% | 223.7% | 353.9% | 500.6% | 328.6% | 4,570.8% |
| Efficiency | ||||||||||
| Days sales outstanding | 53.0 | 59.8 | 87.0 | 70.4 | 282.2 | 121.6 | 85.2 | 60.8 | 32.4 | 469.0 |
| Days of inventory on hand | 916.1 | 1,823.5 | 1,452.6 | 1,077.8 | 600.9 | 273.2 | 261.7 | 357.3 | 515.2 | 2,256.8 |
| Days payables outstanding | 675.6 | 957.8 | 966.0 | 970.5 | 757.8 | 562.6 | 514.9 | 842.6 | 1,631.8 | 3,833.1 |
| Cash conversion cycle (days) | 293.5 | 925.5 | 573.5 | 177.7 | 125.3 | -167.7 | -168.0 | -424.5 | -1,084.2 | -1,107.3 |
| Receivables turnover | 6.88 | 6.10 | 4.20 | 5.19 | 1.29 | 3.00 | 4.28 | 6.00 | 11.27 | 0.78 |
| Payables turnover | 0.54 | 0.38 | 0.38 | 0.38 | 0.48 | 0.65 | 0.71 | 0.43 | 0.22 | 0.10 |
| Inventory turnover | 0.40 | 0.20 | 0.25 | 0.34 | 0.61 | 1.34 | 1.39 | 1.02 | 0.71 | 0.16 |
| Asset turnover | 0.25 | 0.22 | 0.20 | 0.24 | 0.09 | 0.24 | 0.15 | 0.10 | 0.18 | 0.02 |
| Average receivables | $1.7M | $1.9M | $2.3M | $2.3M | $3.4M | $3.1M | $1.3M | $735,420 | $386,824 | $181,838 |
| Average payables | $7.0M | $5.1M | $5.4M | $5.4M | $4.8M | $5.1M | $5.4M | $6.4M | $3.9M | $545,731 |
| Average inventory | $9.5M | $9.8M | $8.1M | $6.0M | $3.8M | $2.5M | $2.7M | $2.7M | $1.2M | $321,312 |
| Intangibles / total assets | 41.8% | 34.6% | 39.6% | 47.3% | 42.5% | 56.8% | 71.5% | 77.3% | 88.5% | 0.0% |
Computed from JAGX's annual financial statements (latest annual report filed April 7, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
JAGX valuation and financial ratios
Jaguar Health earned a return on invested capital of −116.5% in fiscal 2025. It ended the year with $43.6 million of debt and $1.0 million in cash and short-term investments, net debt of $42.6 million. It returned $31.1 million to shareholders: $0 in dividends and $31.1 million in share buybacks, 538% of free cash flow.
See the JAGX income statement, the JAGX chart for price history, or the JAGX stock overview for the latest quote and news.
JAGX key metrics FAQ
What is Jaguar Health's ROIC?
Jaguar Health's return on invested capital was −116.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Jaguar Health have?
Jaguar Health had total debt of $43.6 million at the end of fiscal 2025.
Does Jaguar Health buy back its shares?
Yes. Jaguar Health spent $31.1 million on net share repurchases in fiscal 2025.
What is Jaguar Health's current ratio?
Jaguar Health's current ratio was 0.50 at the end of fiscal 2025: current assets were 0.50 times current liabilities.